Discussant - Phase Ia/Ib dose-escalation study of the anti-TIGIT  tiragolumab as a single agent and in combination with atezolizumab in advanced solid tumors - Michele Teng #AACR20 $RHHBY $MRK $RCUS $MREO $SGEN 4/x

role of CD155 (recent paper in Clin Cancer Res) https://t.co/k1lgEhMnYI